Busulfan and melphalan versus carboplatin, etoposide, and melphalan as HD chemotherapy for HR neuroblastoma (HR-NBL1 ph3 trial /SIOPEN)
Previous
Previous
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting
Next
Next